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Thiazolidinediones, including troglitazone, and 15-deoxy-D12,14-
prostaglandin J2 (15d-PGJ2), a metabolite of prostaglandin J, have
been identified as ligands for peroxisome proliferator-activated
receptor (PPAR) g (Forman et al, 1995; Kliewer et al, 1995).
PPARg has been reported to play an important role in insulin
sensitization and adipocyte (Chawla et al, 1994) and mon-
ocyte/macrophage (Tontonoz et al, 1998; Pelton et al, 1999) differ-
entiation. Expression and activation of PPARg in fibroblastic and
myoblastic cells triggers the adipocyte gene expression cascade
and leads to the development of the adipose phenotype (Tontonoz
et al, 1994; Hu et al, 1995). This receptor and its heterodimeric
partner, retinoid X receptor (RXR) a, which binds to 9-cis retinoic
acid (9-cis RA), form a DNA-binding complex. Transcriptional
activity of the PPARg/RXRa heterodimer is maximal in the pres-
ence of both PPARg and RXRa activators (Mukherjee et al, 1997).
Recent reports have indicated that PPARg also express in different
tissues and PPARg ligands can induce growth inhibition in human
prostate cancer cells (Kubota et al, 1998), colon cancer cells
(Brockman et al, 1998; Sarraf et al, 1998; Kitamura et al, 1999)
and liposarcoma cells (Tontonoz et al, 1997). Induction of apop-
tosis by PPARg has been demonstrated in mammalian cells
(Elstner et al, 1998; Clay et al, 1999; Keelan
et al, 1999). A recent study has demonstrated expression of
PPARg in human gastric cancer cell line MKN45 and reported
troglitazone-induced growth inhibition and apoptosis (Takahashi
et al, 1999). To evaluate the possibility of PPARg ligands in gastric
cancer treatment, in the present study we have investigated PPARg
expression in human gastric carcinoma tissues and checked
growth inhibitory effects of different types of PPARg agonists on
four cell lines.
MATERIALS AND METHODS
Immunohistochemistry for PPARg protein
Human gastric cancer tissues were obtained at the time of surgical
removal with the informed consent of the patients. The corre-
sponding normal gastric tissues were also obtained simultane-
ously. These samples were immediately frozen and stored in liquid
nitrogen until immunohistochemistry. Identification of cancer and
non-cancer specimens was confirmed by light microscopic exami-
nation. From these samples, 3-mm thick cryostat tissue sections
were mounted on poly-L-lysine-coated slides and stored at –20°C.
The slides were air-dried for 30 min and fixed in acetone at –4°C
for 10 min. Samples were then incubated with normal horse serum
(Vector Laboratories, Burlingame, CA, USA) for 30 min, followed
by incubation with a mouse monoclonal antibody recognizing
human PPARg (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
for 120 min. Mouse IgG1 myeloma protein MOPC-21 (Sigma, St
Louis, MO, USA) was used as control. After washing the sections
with phosphate buffered saline (PBS), they were incubated with
biotinylated horse anti-mouse IgG (Vector Laboratories) for
30 min. Bound antibody was detected using the avidin–biotin
peroxidase method (ABC Kit; Vector Laboratories). Peroxidase
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activity was subsequently detected by 3,3¢-diaminobenzidine
(Sigma) in 0.05 M Tris-HCl for 10 min at room temperature,
followed by haematoxylin staining. After dehydration in a graded
alcohol series, the sections were cleared in xylene.
Cell lines
Four human gastric cancer cell lines, MKN-7, MKN-28, MKN-45
and AGS were used in this study. MKN-7, MKN-28 and MKN-45
were obtained from Riken Cell Bank (Ibaraki, Japan) and AGS
from the American Type Culture Collection (ATCC, Rockville,
MD, USA). The MKN-45 and AGS were established from poorly
differentiated gastric carcinoma and MKN-7 and MKN-28 from
well and moderately differentiated gastric carcinoma. MKN-7,
MKN-28 and MKN-45 cells were cultured in RPMI 1640 (ICN
Biomedicals, Ohio, USA) and AGS cells in Ham’s F12 (ICN)
supplemented with 10% fetal bovine serum in an atmosphere of
5% CO2 at 37°C in a humidified incubator.
RNA extraction
Total RNA was extracted by the acid guanidinium phenol chloro-
form method using Isogen (Nippon Gene, Tokyo, Japan). 5 ´ 106
cells were shaken vigorously for 1 min in 0.8 ml of Isogen solution
and 0.2 ml of chloroform. After centrifugation at 12 000 rpm at
4°C for 15 min, the aqueous phase was transferred to a fresh tube,
an equal volume of isopropanol was added and the mixture was
allowed to stand at 4°C for 15 min, followed by centrifugation at
12 000 rpm at 4°C for 15 min. The RNA precipitate was rinsed
with 75% ethanol and air-dried for 5 min. Finally, RNA was
dissolved in 50 ml of distilled water containing 0.1% diethyl-
pyrocarbonate and the RNA concentration was measured by
spectrophotometry at 260 nm.
Reverse transcription-polymerase chain reaction
Five mg total RNA extracted from each cell line was reverse tran-
scribed to cDNA using a First Strand cDNA Synthesis Kit
(Stratagene, Toyobo, Japan) according to the manufacturer’s
instructions using oligo (dT) primer. Synthesized cDNA was
stored at –80°C until used for the polymerase chain reaction
assay (PCR). The primers used for amplifying PPARg cDNA
were 5¢-TCTGGCCCACCAACTTTGGG-3¢ and 5¢-CTTC-
ACAAGCATGAACTCCA-3¢ and for RXRa cDNA were
5¢-CTCTCAGGTTGAACTCACCT-3¢ and 5¢-ATCTCTGACAG-
CCTGTCTCG-3¢. As internal control, RT-PCR for b-actin mRNA
was also performed using the primers (5¢-ATCTGGCACCA-
CACCTTCTACAATGAGCTGCG-3¢ and 5¢-CGTCATACTCCT-
GCTTGCTGATCCACATCTGC-3¢). After denaturation of the
samples at 95°C for 10 min, PCR was carried out in a DNA
thermal cycler (PE Biosystems, Foster City, CA, USA) for 35
cycles (95°C for 1 min, 55°C for 30 s and 72°C for 1 min)
followed by 72°C for 10 min. 5 ml of PCR products were elec-
trophoresed in 1% agarose gels stained with ethidium bromide.
The detection of amplified DNA bands at the expected lengths
(PPARg 360 bp, RXRa 422 bp, b-actin 838 bp) was confirmed
and products were also directly sequenced by ABI Prism 310
Genetic Analyser using BigDye terminator Cycle Sequencing
Reagent (PE Biosystems).
Northern blot analysis
From each cell line, 20 mg total RNA was electrophoresed in
formaldehyde-containing 1.2% agarose gels and transferred to a
nitrocellulose membrane (Schleicher and Schuell, Dassel,
Germany), followed by fixation with UV cross-linker (Funa-
UV-Linker; Funakoshi, Tokyo, Japan). The probes used for
Northern blot analysis were a 32P-labelled 360 bp cDNA fragment
of human PPARg and a 32P-labelled 838 bp cDNA fragment of
human b-actin. After 4 h prehybridization and 24 h hybridization
at 42°C, the filters were washed first for 10 min and then for
15 min at 37°C in 2 ´ saline-sodium citrate (SSC) containing 0.2%
sodium dodecyl sulphate (SDS), and finally at 50°C in 0.1 ´ SSC
containing 0.2% SDS for 20 min. Autoradiography was performed
using image analyser BAS 2000 II (Fuji Photo Film Co, Tokyo,
Japan).
Western blot analysis
Protein concentrations were measured using Bio-Rad Protein
Assay Reagent (Bio-Rad Laboratories, Richmond, CA, USA)
following the manufacturer’s instruction. 50 mg of protein was
separated by 10% SDS PAGE. After electrophoresis, the proteins
were transferred to polyvinylidene membranes (Amersham
International, Buckingham, UK), blocked in TBS-Tween with
10% skimmed milk at 4°C for 1 h, subsequently reacted with
primary monoclonal antibody overnight and washed. After
reacting with a mouse peroxidase-conjugated antibody detection
agent (Amersham), signal was detected by chemiluminescence
using the ECL detection system (Amersham). For detection
of PPARg, mouse anti-human PPARg monoclonal antibody
(SC-7273, Santa Cruz) was used. As an internal control, b-actin
was detected with mouse monoclonal antibody (AC-15, Sigma).
Growth assessment and chemicals
Human gastric cancer cells were seeded (1 ´ 105 cells ml–1) in
24-well plates and treated for 48 h with each chemical agent.
Troglitazone was kindly provided by Sankyo Pharmaceutical Co
(Tokyo, Japan) and dissolved in dimethyl sulphoxide (DMSO).
Indomethacin (Nacalai tasque, Kyoto, Japan) was also dissolved in
DMSO. 9-cis RA (Sigma) and 15d-PGJ2 (Calbiochem, La Jolla,
CA, USA) were dissolved in ethanol. Vehicle in the medium did
not exceed 0.1%. After 48 h treatment with drug, 1 mCi [Methyl-
3H] thymidine (Amersham) was added to each well and incubated
for 4 h. Cells were harvested onto a glass fibre filter mat using a
Cell Harvester (Inotech, Switzerland). After the mat was dried
[3H] thymidine incorporation was measured by 1450 Microbeta
scintillation counter (Wallac, Oy, Turku, Finland). Assessment of
cell proliferation was performed in triplicate and repeated three
times.
Cell cycle analysis
Cell cycle profiles were performed on all four gastric cancer cell
lines. Cells were treated with 10 mM troglitazone for 48 h,
collected after brief trypsinization, washed with PBS, and fixed in
cold 70% ethanol. Then the samples were treated with RNase,
stained with 50 mg ml–1 propidium iodide (PI), and analysed by
EPICS Elite flow cytometer (Coulter Electronics, FL, USA).Detection of apoptosis in gastric cancer cells
To detect apoptotic cells, the expression of annexin V on the cell
surface was examined by flow cytometry. Annexin V detects phos-
phatidylserine on the outer cytoplasmic membrane, which occurs
during the loss of phospholipid asymmetry early in the apoptotic
process. After 48 h treatment with troglitazone, the supernatant
was removed and the adherent cells were harvested with 0.05%
trypsin. The cells were washed three times with PBS and incu-
bated with FITC-conjugated annexin V antibody (Immunotech,
Marseille, France) and PI in medium containing 1.5 mM CaCl2 at
4°C for 15 min. After incubation, cells were analysed by flow
cytometry (FACScan; Becton Dickinson, San Jose, CA, USA).
The assay was done in triplicate and repeated three times. PI-
negative and annexin V-positive cells were considered as early
apoptotic cells.
Nuclear morphology of apoptosis was assessed by staining with
Hoechst 33258 (Calbiochem); cells with condensed or fragmented
nuclei were recognized as apoptotic cells by fluorescence micro-
scopy (Olympus, Tokyo, Japan).
Statistical analysis
Data are expressed as means ± SE. Values were compared and
significant differences between means were determined by
Analysis of variance (ANOVA). Multiple comparisons were done
by Sheff’s test after ANOVA and P values < 0.05 were considered
statistically significant.
RESULTS
Expression of PPARg protein in human gastric cancer
Surgically obtained tissue from gastric adenocarcinoma expressed
PPARg protein, as shown by immunohistochemistry (Figure 1).
We stained sections from 12 selected cases – four poorly differen-
tiated, four moderately differentiated and four poorly differenti-
ated cancers. The staining result was consistent in all cases. PPARg
protein was expressed not only in well differentiated, moderately
differentiated and poorly differentiated gastric adenocarcinoma,
but also normal mucosa with intestinal metaplasia adjacent to
cancer.
PPARg and RXRa expression in human gastric cancer
cell lines
We used RT-PCR to determine the expression of PPARg and
RXRa mRNA in four gastric cancer cell lines: MKN-7, MKN-28,
MKN-45 and AGS. As shown in Figure 2A, PPARg and RXRa
mRNA were expressed in all the four cell lines. PPARg mRNA
was expressed at relatively higher levels in MKN-7 and MKN-45
cells (Figure 2B). PPARg protein was also detected in all four cell
lines, but only at a low level in AGS cells. As an internal control,
we demonstrated b actin expression (Figure 2C).
Growth assessment of human gastric cancer cell lines
We evaluated the effect of various ligands on the proliferation of
the four gastric cancer cell lines by [3H]-thymidine incorporation.
There was a dose-dependent reduction in [3H]-thymidine uptake
after treatment with troglitazone for 48 h in three cell lines,
MKN-28, MKN-45, and AGS. Troglitazone induced a significant
(P < 0.05) antiproliferative effect at a concentration of 10 mM in
these cell lines. Treatment with 15d-PGJ2, a natural ligand for
PPARg, also reduced [3H]-thymidine uptake in MKN-45 and AGS
cells. However, in MKN-7 cells, increased incorporation of [3H]-
thymidine was observed after treatment with troglitazone or 15d-
PGJ2. Indomethacin, a ligand for PPARg (Lehmann et al, 1997),
and 9-cis RA, a ligand for RXRa, showed weak growth suppres-
sion at high concentrations (Figure 3), but their effects were
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Figure 1 PPARg protein expression in human gastric cancer tissues.
PPARg protein is expressed in both well differentiated (A) and poorly
differentiated (B) adenocarcinoma. In addition, PPARg protein is also present
in non-cancerous tissue with intestinal metaplasia (C) adjacent to cancer
tissueweaker than that of troglitazone. Furthermore, we tested the effect
of simultaneous administration of ligands of PPARg and RXRa on
the proliferation of gastric cancer cells. As shown in Figure 4, 9-
cis RA augmented the growth inhibitory effect of troglitazone on
gastric cancer cells. The experiment was also done on other cell
lines and as the result was similar and there was no difference from
PPARg ligand response, detailed data are not shown.
Changes of cell cycle profile by treatment with
troglitazone
To investigate the mechanism of growth inhibition by PPARg acti-
vation, we performed flow cytometric analysis to test the effect of
troglitazone on the cell cycle profile. Representative cell cycle
profiles are shown in Figure 5. Troglitazone-treated MKN-28,
MKN-45 and AGS cells exhibited a significant increase in G1
phase associated with a decrease in S phase. On the other hand, G1
phase decreased slightly with an S phase increase in MKN-7.
These results suggest that activation of PPARg usually inhibits
most cellular growth via induction of cell cycle arrest in G1,
however, in some cell lines such as MKN-7, they may induce a
proliferative response.
Detection of apoptosis in human gastric cancer cells
We evaluated whether PPARg ligands induce apoptosis in human
gastric cancer cells. Flow cytometric analysis was used to quantify
apoptosis of cells treated with troglitazone 10 mM for 48 h.
Treatment with troglitazone resulted in an increase of annexin
V-positive cells in MKN-28, MKN-45, and AGS cells, but no
increase in MKN-7 cells (Figure 6). As shown in Figure 7, we also
confirmed morphologically the presence of apoptotic cells with
condensed or fragmented nuclei by staining with Hoechst 33258.
DISCUSSION
PPARg, a subtype of the PPAR family, is predominantly expressed
in adipose tissue, where it controls critical steps of lipid home-
ostasis and functions as a key trigger of adipocyte differentiation.
PPARg expression has also been found in cells from various
lineages, such as liposarcoma, human breast cancer, colon cancer,
and prostate cancer. Administration of PPARg ligands was shown
to inhibit the growth of these cells. In addition, a recent report
demonstrated that in patients with advanced liposarcoma, troglita-
zone induced histological and biochemical differentiation of
tumour cells to adipocytes (Demetri et al, 1999). These observa-
tions suggest that induction of terminal differentiation with PPARg
agonists may represent a novel therapeutic approach to human
Expression and activation of PPARg in human gastric cancer 1397
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Figure 2 PPARg expression in human gastric cancer cell lines. (A) PPARg
and RXRa expression at the mRNA level in human gastric cancer cell lines.
From each cell line, 5 mg of total RNA was subjected to RT-PCR. 5 ml aliquot
of the PCR products were electrophoresed in 1% agarose gel. (B) Northern
blot analysis of PPARg expression in human gastric cancer cell lines.
Approximately 20 mg of RNA of each cell line was electrophoresed through
formaldehyde-containing 1.2% agarose gels and transferred to a
nitrocellulose membrane. Hybridization was performed using a human
PPARg cDNA probe labelled with [a-32P] dCTP. The b-actin level shown in the
lower lane is to demonstrate that equivalent amounts of RNA were loaded on
each lane. (C) PPARg protein expression in human gastric cancer cell lines.
Approximately 50 mg of protein from each cell line was separated on an
SDS-PAGE gel, probed with an anti-PPARg antibody, and visualized with
enhanced chemiluminescence. As an internal control, b-actin was detected
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Figure 3 Dose-dependent effect of troglitazone and 15d-PGJ2 on growth
inhibition in human gastric cancer cell lines. Cells were seeded into 24-well
plates at a density of 1 ´ 105 cells well–1 and treated with troglitazone, 9-cis
RA, indomethacin and 15d-PGJ2. After culture for 48 h, DNA synthesis was
measured as [3H] thymidine incorporation. Results are expressed as a
percentage of control and each point represents the mean ± SE of three
independent experiments. *P < 0.05 compared with untreated control.
l l = troglitazone, n n = 9-cis RA, s s = indomethacin, l = 15d-PGJ2malignancies. However, in colon cancer cells, the growth
suppressing effect of PPARg agonists, which was clearly shown in
in vitro studies, was not necessarily confirmed by in vivo studies.
Several reports have indicated that activation of PPARg promotes
the development of colon tumours, not only in C57BL/6J-
APCmin/+ mice, a clinically relevant model for human familial
adenomatous polyposis, but also in animal models that develop
sporadic colon cancer (Lefebvre et al, 1998; Saez et al, 1998).
The expression of PPARg in human gastric cancer has not been
fully elucidated. We found strong expression of PPARg in surgi-
cally resected human gastric cancer specimens irrespective of the
differentiation of the cancer tissue. Furthermore, gastric antral
mucosa with intestinal metaplasia was also shown to express
PPARg protein. This is the first report showing the presence of
PPARg not only in gastric cancer but also in non-cancerous
mucosa of human stomach. In addition, we demonstrated an
antiproliferative effect of PPARg ligands in vitro. A significant
growth inhibitory effect of troglitazone or 15d-PGJ2 was observed
only in moderately and poorly differentiated adenocarcinoma cell
lines. Conversely, growth inhibition by these ligands was not
found in a well differentiated adenocarcinoma cell line, MKN-7,
even at higher concentrations. Therefore, the role of PPARg in
growth control of human gastric cancer cells may depend on
cellular differentiation, and well differentiated cancers may lose
their sensitivity to growth control by PPARg.
In this study, AGS cell line with low level PPARg protein
expression showed a significant antiproliferative effect, but
MKN7 cells with high PPARg expression did not. It seems diffi-
cult to explain the discrepancy between quantity of PPARg protein
expression and the anti-proliferative effect induced by PPARg
agonists on gastric carcinoma cell lines. Due to involvement of
multiple factors like RXRa, cofactors, hsp70, etc, in PPARg acti-
vation and binding to PPARg-responsive element (PPRE), PPARg
agonist-mediated response may not depend only on the quantity of
PPARg protein present in a cell line. One possible explanation
is PPARg mutation in MKN7. Defect in other factors necessary for
PPARg activation and binding to PPARg-responsive element
(PPRE), or defect in the target gene(s) after PPARg activation
should also be considered as another possibility for ineffective
response in MKN-7.
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Figure 4 Effect of simultaneous treatment with troglitazone (TRO) and 9-cis
RA on growth inhibition. AGS cells were seeded (1 ´ 105 cells well–1) and
treated with troglitazone and/or 9-cis RA. After culture for 48 h, [3H] thymidine
incorporation was measured. Results are expressed as a percentage of
control. *P < 0.05 compared with untreated control
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Figure 5 Effect of a PPARg ligand on cell cycle profile. Cells were cultured
in presence of troglitazone (10 mM) or DMSO for 48 h, then harvested, fixed,
stained with PI and analysed by flow cytometry. The values represent the
number of cells in a phase of the cell cycle as a percentage of total cells
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Figure 6 Effect of a PPARg ligand on apoptosis of gastric cancer cells.
Cells were incubated in presence of troglitazone (10 mM) or DMSO for 48 h,
then harvested and incubated with FITC-conjugated annexin V antibody and
PI. Cells were analysed by flow cytometry; PI-negative and annexin
V-positive cells were considered as early apoptotic cellsAlthough the mechanism of growth inhibition via PPARg in
human gastric cancer cells has not been fully elucidated, it may be
connected to the cell cycle, as reported with other mammalian
cells. In our study, G1 cell cycle arrest was observed in moderately
differentiated MKN-28 cells and in poorly differentiated AGS and
MKN-45 cells after treatment with troglitazone. These results are
comparable with that of colon cancer cells (Brockman et al, 1998;
Kitamura et al, 1999). Therefore, growth inhibition by PPARg
ligands may be, at least in part, related to cell cycle arrest at
G1 phase. In MKN-7 cells, cell cycle analysis after troglitazone
treatment showed an increase in S phase with decreased G1 phase.
Increased S phase in MKN-7 is also compatible with the [3H]
thymidine incorporation result of MKN-7 which show an increase
too.
To investigate other possible mechanisms of the antiprolifera-
tive effect of PPARg activation, the effect of PPARg ligands on
cellular apoptosis was studied in gastric cancer cells. PPARg-
induced apoptosis has recently been demonstrated in human breast
cancer (Elstner et al, 1998; Clay et al, 1999), choriocarcinoma
(Keelan et al, 1999), prostate cancer (Kubota et al, 1998) and
endothelial cells (Bishop-Bailey and Hla, 1999). In the present
study, treatment with troglitazone resulted in an increase in the
number of apoptotic cells. Thus, apoptosis and cell cycle arrest are
possible mechanisms for the growth inhibitory effect of PPARg
activation.
Recent reports have indicated that PPARg ligands also suppress
the clonal growth of leukaemia cell lines (Asou et al, 1999; Hirase
et al, 1999; Sugimura et al, 1999). In fact, differentiation therapy
with all-trans retinoic acid, a ligand for RARa, has already
become one of the standard treatments for acute promyelocytic
leukaemia (APML) (Huang et al, 1998; Warrell et al, 1991).
Therapy that induces apoptosis and differentiation has recently
been considered as a possible alternative treatment for various
neoplastic diseases other than APML.
In the present study, we have shown that activation of one of the
DNA-binding nuclear receptors PPARg or RXRa has a growth
suppressing effect on certain poorly differentiated gastric cancer
cells. Poorly differentiated gastric cancer is frequently observed
and it is the most lethal malignant neoplasm in several countries,
including Japan. Therefore, therapy with potent PPARg agonists
may be a promising future approach for the treatment of poorly
differentiated gastric cancer. Further studies will be necessary
before PPARg ligands can be used in patients with gastric cancer,
but this nuclear receptor may provide a novel target for the
treatment of gastric cancer in humans.
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